BioHarvest Sciences Inc. has announced a new contract through its Botanical Synthesis CDMO Services division to develop a plant-based fragrance compound. The agreement, which includes milestone-based payments and a non-disclosure agreement for Stage 1, expands BioHarvest's platform into the fragrance market. Utilizing its advanced AI-assisted research capabilities, the company identified specific plant species to develop a cell bank for efficient production of fragrance molecules. Stage 1 will use BioHarvest's proprietary Botanical Synthesis platform to replicate and multiply the plant's targeted cells. A successful outcome could lead to Stage 2, involving production in liquid media, paving the way for future manufacturing. CEO Ilan Sobel highlighted the contract as validation of the platform's ability to deliver scalable solutions while conserving threatened plant species.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。